Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
226
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Promising Results in Its Pursuit of Safe, Effective Treatments for Large, Underserved Population of Plaque Psoriasis Patients

- Scinai announced positive results suggesting the therapeutic potential of its anti-IL-17 VHH antibodies (NanoAbs) in treating plaque psoriasis
- The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis
- The study also revealed that the outer skin layers regained their normal appearance
- The company aims to provide safe, efficacious, specific, and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients
- Scinai is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for psoriasis and intends to begin in-vivo animal studies early next year

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical and biotechnology company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological therapeutics, recently announced encouraging results from a preclinical study that suggest the therapeutic potential of the anti-interleukin 17 (“IL-17”) nanosized antibodies (“NanoAbs”) to relieve symptoms of plaque psoriasis (https://nnw.fm/RoNs0 ).

Plaque psoriasis is the most common psoriasis phenotype, affecting 80-90% of psoriatic patients (https://nnw.fm/AseXg). It is caused by the excessive proliferation of keratinocytes (skin cells that, by secreting keratin, strengthen the skin, shield against UV penetration, and protect against microbial invasion), “the complex interaction of activated innate and adaptive immune cells (notably dendritic cells and T cells) that infiltrate the skin, and chronic inflammation” (https://nnw.fm/mih1h ). Several cytokines are at the center of the activation and subsequent infiltration of the immune cells; among these, IL-12, IL-17, and IL-23 are currently considered the most important therapeutic targets.

So far, companies like Novartis (NYSE: NVS) and Eli Lilly (NYSE: LLY) have launched biological treatments, primarily monoclonal antibodies (“mAbs”), that target IL-17A, a member of the IL-17 family. On its part, Novartis developed and is commercializing Cosentyx(R), which was approved by the U.S. Food and Drug Administration (“FDA”) in 2015 (https://nnw.fm/b3t8I). As well, the FDA approved Eli Lilly’s Taltz(R) in 2016 (https://nnw.fm/IbWQW ). More recently, UCB received European Commission approvals to market BIMZELX(R) for the treatment of adults with active psoriatic arthritis (https://nnw.fm/PkLtY ).

“All the above-mentioned antibodies, indicated only for moderate to severe psoriasis patients, are administered by subcutaneous injection for systemic drug distribution and carry risk of considerable side effects. These drugs are also expensive as they require chronic, life-long, bi-weekly injections, each at a cost of several thousand dollars,” explained Scinai in a news release. “Mild psoriasis, which accounts for 50% of plaque psoriatic patients, unfortunately has no safe and affordable biological drug available.”

Having recently signed an exclusive worldwide license agreement for the development and commercialization of a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, starting with psoriasis (https://nnw.fm/iH3Kz ), Scinai is on a quest to provide safe, effective, and affordable treatment for patients with mild to moderate psoriasis. The company’s preclinical study, ergo, brings it closer to actualizing its vision.

As part of the study, researchers constructed a 3D biological skin model out of a scaffold mounted with various skin cells to generate layers that mimic the structure of human skin and induced it to express plaque psoriasis. They then introduced the anti-IL-17 NanoAbs into the model either subcutaneously or topically to test them as a potential treatment for the condition.

The preclinical study showed that the introduction of the NanoAbs downregulated the standard molecular markers, S100A7, CXCL1, and CCL20, that are often overexpressed in plaque psoriasis. Moreover, the study revealed that the stratum corneum (the outer skin layers) regained its normal appearance. These results, the company said, suggest the potential for a highly efficacious, specific, yet safer and more convenient treatment for the large and underserved population of mild to moderate plaque psoriasis patients.

According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis, with more than 8 million of them living in the U.S. (https://nnw.fm/SAsFB ). Among these patients, 51.8%, 35.8%, and 12.4% have mild, moderate, and severe disease, respectively, according to a study that sampled patients aged 25 to 64 years (https://nnw.fm/t8Zvz ). This means that more than 80% of patients with psoriasis present with mild to moderate severity (https://nnw.fm/2hY5B ), with the majority having mild illness, yet the treatments are geared toward the minority.

Scinai aims to tap into this huge underserved market, providing efficacious psoriasis treatment that is designed to be conveniently administered locally to the dermis and engineered in a way that is expected to prevent systemic side effects. The company is conducting an ex-vivo study to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for psoriasis. This new study seeks to evaluate the effective dose and schedule of treatment to guide in-vivo animal studies planned for early 2024.

For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer


Scanner Tech Corp (SCNI) Stock Research Links

SCNI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 100

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 49

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 65

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 67

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading

Top 5 Most Recently Viewed Articles

Latham Plunge Pools Earns Top Honors as Innovative Retail Design

Updated Category News Views 252

Latham Plunge Pools: Celebrating Innovation in Outdoor Living Latham Group, Inc. (NASDAQ:SWIM), the leading designer and manufacturer of in-ground swimming pools, has recently been recognized for its exceptional contribution to the backyard experience. Their latest achievement, the "Most Innovative Product for Retailers" award, was proudly received at the prestigious...

Continue Reading
HF Sinclair Corporation Announces Upcoming Earnings Webcast

Updated Category News Views 120

HF Sinclair Corporation Earnings Announcement HF Sinclair Corporation (NYSE: DINO) is preparing to share its financial results for the third quarter, which ends on September 30, 2024. This important announcement is set for October 31, 2024, and will take place before the market opens on the NYSE. Details of the Earnings Release All investors and interested individuals...

Continue Reading
Verde Resources Unveils VerdePlus, Paving the Way for Green Infrastructure

Updated Category News Views 135

Verde Resources Inc. Introduces VerdePlus for Sustainable Solutions Verde Resources Inc. (OTCQB: VRDR) is proud to announce a transformative step in their efforts towards sustainable infrastructure with the launch of VerdePlus Inc. This innovative subsidiary, developed through a partnership with Nature Plus Inc. (NPI), aims to set new standards in low-carbon construction...

Continue Reading
East Palestine Settlement Center Closure: What You Need to Know

Updated Category News Views 229

Important Closure of the East Palestine Settlement Center The East Palestine Settlement Center, specifically created to aid those affected by a recent train derailment, will be closed on Friday, January 17. This decision comes in response to pending traffic restrictions expected in the surrounding area, which may hinder access to the facility. Rescheduling and Future...

Continue Reading
Aditx Therapeutics Faces Challenges with Stock at $0.18 Low

Updated Category News Views 280

Aditx Therapeutics Faces Significant Stock Decline Aditx Therapeutics Inc (ADTX) has recently encountered a challenging period as its stock price plummeted to a 52-week low of $0.18. This significant decrease illustrates a dramatic 1-year change of -99.9%. Such a downturn highlights the tumultuous state of the biotech company, which is currently grappling with a market...

Continue Reading